Opinion: Out-of-pocket drug costs for Medicare beneficiaries need to be reined in

This year, 56 million U.S. seniors will pay more for Medicare prescription drug coverage, partly due to a single drug most will not take — Aduhelm, a newly approved, expensive, and controversial Alzheimer’s drug.

In late 2021, the Centers for Medicare and Medicaid Services announced one of the largest increases ever — nearly 15% — to monthly premiums for Medicare Part B, which provides coverage for injected or infused medications administered by clinicians, among other outpatient services. CMS’s rationale? The premium price hike was needed in anticipation of potential future coverage of Aduhelm, initially priced at $56,000 per year.

Read the rest…